top
Please input keywords
Order
*Country
日本
アメリカ
中国
オーストラリア
シンガポール
イギリス
フランス
ドイツ
スイス
イタリア
カナダ
韓国
オランダ
ベルギー
スウェーデン
その他
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hCLDN18.2 BxPC-3
Common name
B-hCLDN18.2 BxPC-3 Catalog number    321827
Aliases / Disease  Pancreatic adenocarcinoma
Organism
Human Strain  Human
Tissue types Pancreas Tissue  Pancreas

Description


The exogenous promoter and human CLDN18.2 coding sequence were inserted into the BxPC-3 cells genome randomly. Human CLDN18.2 is highly expressed on the surface of B-hCLDN18.2 BxPC-3 cells.


Application


B-hCLDN18.2 BxPC-3 cells have the capability to establish tumors in vivo and can be used for efficacy studies.


Targeting strategy


Gene targeting strategy for B-hCLDN18.2 BxPC-3 cells. The exogenous promoter and human CLDN18.2 coding sequence were inserted into the BxPC-3 cells genome randomly.


Protein expression analysis

from clipboard

CLDN18.2 expression analysis in B-hCLDN18.2 BxPC-3 cells by flow cytometry. Single cell suspensions from B-hCLDN18.2 BxPC-3 cultures were stained with species-specific anti-CLDN18.2 antibody. Human CLDN18.2 was detected on the surface of B-hCLDN18.2 BxPC-3 cells. The 1-A04 clone of B-hCLDN18.2 BxPC-3 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

from clipboard


Subcutaneous homograft tumor growth of B-hCLDN18.2 BxPC-3 cells. B-hCLDN18.2 BxPC-3 cells (1x107) and wild-type BxPC-3 cells (1x107) were subcutaneously implanted into B-NDG mice (female, 9-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hCLDN18.2 BxPC-3 cells were able to establish tumors in vivo and can be used for efficacy studies.

Protein expression analysis of tumor cells


from clipboard



B-hCLDN18.2 BxPC-3 cells were subcutaneously transplanted into B-NDG mice (n=5), and on 77 days post inoculation, tumor cells were harvested and assessed for human CLDN18.2 expression by flow cytometry. As shown, human CLDN18.2 was highly expressed on the surface of tumor cells. Therefore, B-hCLDN18.2 BxPC-3 cells can be used for in vivo efficacy studies of novel CLDN18.2 therapeutics.